---
layout:     post
title:      nucleic acid drugs list
date:       2021-05-03
author:     Xuan
catalog:    true
tags: Tech
---

# List of nucleic acid drugs in clinical trials
# [Reference](https://doi.org/DOI:10.1002/adfm.202011103)

| Nucleic acid | Name                              | Company                                                      | Nanoparticle system/                                                                             | Disease                                                         | Clinical trial       | ID number   |
| ------------ | --------------------------------- | ------------------------------------------------------------ | ------------------------------------------------------------------------------------------------ | --------------------------------------------------------------- | -------------------- | ----------- |
| ASO          | Pelacarsen (AKCEA-APO(a)-LRx)     | Ionis, Akcea, and Novartis                                   | Gen 2+ (LICA)                                                                                    | Hyperlipoproteinemia(a) and cardiovascular disease              | Phase 2/3            | NCT03070782 |
| ASO          | AKCEA-TTR-LRx                     | Ionis and Akcea                                              | Gen 2+ (LICA)                                                                                    | Hereditary transthyretin-mediated amyloid polyneuropathy (ATTR) | Phase 3              | NCT04136184 |
| ASO          | Vupanorsen                        | Ionis, Akcea, and Pfizer                                     | Gen 2+ (LICA) (3 GalNAcs are attached on the 5′ end of modified ASO)                             | Cardiovascular disease                                          | Phase 2              | NCT04459767 |
| ASO          | AKCEA-APOCIII-LRx                 | Ionis and Akcea                                              | Gen 2+ (LICA)                                                                                    | Cardiovascular disease/familial chylomicronemia syndrome        | Phase 2              | NCT03385239 |
| ASO          | IONIS-FB-LRx                      | Ionis and Roche                                              | Gen 2+ (LICA)                                                                                    | IgA nephropathy                                                 | Phase 2              | NCT04014335 |
| ASO          | IONIS-AGT-LRx                     | Ionis                                                        | Gen 2+ (LICA)                                                                                    | Hypertension                                                    | Phase 2              | NCT04083222 |
| ASO          | IONIS-FXI-LRx                     | Ionis and Bayer                                              | Gen 2+ (LICA)                                                                                    | Clotting disorders                                              | Phase 2              | NCT03582462 |
| ASO          | IONIS-GHR-LRx                     | Ionis                                                        | Gen 2+ (LICA)                                                                                    | Acromegaly                                                      | Phase 2              | NCT03548415 |
| ASO          | IONIS-PKK-LRx                     | Ionis                                                        | Gen 2+ (LICA)                                                                                    | Hereditary angiodema                                            | Phase 2              | NCT04030598 |
| ASO          | IONIS-TMPRSS6-LRx                 | Ionis                                                        | Gen 2+ (LICA)                                                                                    | β-Thalassemia                                                   | Phase 2              | NCT04059406 |
| ASO          | IONIS-GCGRRx                      | Ionis and Suzhou-Ribo                                        | Gen 2+ (modified ASO)                                                                            | Diabetes                                                        | Phase 2              | No results  |
| ASO          | Tofersen                          | Ionis and Biogen                                             | Gen 2+ (modified ASO)                                                                            | Amyotrophic lateral sclerosis (ALS)                             | Phase 3              | NCT02623699 |
| ASO          | IONIS-C9Rx (BIIB078)              | Ionis and Biogen                                             | Gen 2+ (modified ASO)                                                                            | Amyotrophic lateral sclerosis (ALS)                             | Phase 1/2            | NCT03626012 |
| ASO          | IONIS-MAPTRx (BIIB080)            | Ionis and Biogen                                             | Gen 2+ (modified ASO)                                                                            | Alzheimer’s disease and frontotemporal degeneration             | Phase 2              | NCT03186989 |
| ASO          | ION859 (BIIB094)                  | Ionis and Biogen                                             | Gen 2+ (modified ASO)                                                                            | Parkinson’s disease                                             | Phase 1/2            | NCT03976349 |
| ASO          | ION464 (BIIB101)                  | Ionis and Biogen                                             | Gen 2+ (modified ASO)                                                                            | Multiple system atrophy and Parkinson’s disease                 | Phase 1/2            | NCT04165486 |
| ASO          | IONIS-HBVRx                       | Ionis and GSK                                                | Gen 2+ (modified ASO)                                                                            | Hepatitis B                                                     | Phase 2              | NCT02981602 |
| ASO          | Tominersen (RO7234292)            | Hoffmann-La Roche and Ionis                                  | Gen 2+ (modified ASO)                                                                            | Huntington’s disease                                            | Phase 3              | NCT03761849 |
| ASO          | IONIS-DNM2-2.5Rx                  | Ionis and Dynacure                                           | Gen 2.5 (modified ASO)                                                                           | Centronuclear myopathy                                          | Phase 2              | No results  |
| ASO          | IONIS-AR-2.5Rx                    | Ionis and Suzhou-Ribo                                        | Gen 2.5 (modified ASO)                                                                           | Prostate cancer                                                 | Phase 2              | NCT02144051 |
| ASO          | Danvatirsen                       | Ionis and AstraZeneca                                        | Gen 2.5 (modified ASO)                                                                           | Cancer                                                          | Phase 2              | NCT02983578 |
| ASO          | ION357/QR1123                     | Ionis and ProQR Therapeutics                                 | Gen 2.5 (modified ASO)                                                                           | Autosomal dominant retinitis pigmentosa                         | Phase 1/2            | NCT04123626 |
| ASO (AON)    | QR-313                            | Wings Therapeutics                                           | Hydrogel                                                                                         | Epidermolysis bullosa dystrophica                               | Phase 1/2            | NCT03605069 |
| ASO          | BP1001                            | Bio-Path Holdings Inc.                                       | Liposome (DOPC-based, neutrally charged)                                                         | Acute myeloid leukemia                                          | Phase 2              | NCT02781883 |
| ASO          | Sepofarsen (QR-110)               | ProQR Therapeutics                                           | —                                                                                                | Leber’s congenital amaurosis                                    | Phase 2/3            | NCT03913143 |
| ASO          | GTX-102                           | GeneTX Biotherapeutics LLC and Ultragenyx Pharmaceutical Inc | —                                                                                                | Angelman syndrome                                               | Phase 1/2            | NCT04259281 |
| ASO          | QR-010                            | ProQR Therapeutics                                           | —                                                                                                | Cystic fibrosis                                                 | Phase 1/2            | NCT02532764 |
| ASO          | WVE-120102                        | Wave Life Sciences Ltd.                                      | —                                                                                                | Huntington’s disease                                            | Phase 1/2            | NCT03225846 |
| ASO          | WVE-120101                        | Wave Life Sciences Ltd.                                      | —                                                                                                | Huntington’s disease                                            | Phase 1/2            | NCT03225833 |
| ASO          | Inotersen-IONIS-TTRRX/ISIS-420915 | Ionis, Brigham, and Women’s Hospital                         | —                                                                                                | TTR Amyloidosis                                                 | Phase 2/3            | NCT03702829 |
| ASO          | QR-421a                           | ProQR Therapeutics                                           | —                                                                                                | Retinitis Pigmentosa, Usher syndrome type 2                     | Phase 1/2            | NCT03780257 |
| ASO          | STK-001                           | Stoke Therapeutics                                           | —                                                                                                | Dravet syndrome                                                 | Phase 1/2            | NCT04442295 |
| siRNA        | ARO-AAT                           | Arrowhead Pharmaceuticals                                    | TRiM (GalNAc-siRNA conjugates)                                                                   | Alpha 1 liver disease                                           | Phase 2/3            | NCT03945292 |
| siRNA        | ARO-APOC3                         | Arrowhead Pharmaceuticals                                    | TRiM (GalNAc-siRNA conjugates)                                                                   | Hypertrglyceridemia, Familial chylomicronemia                   | Phase 1/2            | NCT03783377 |
| siRNA        | ARO-ANG3                          | Arrowhead Pharmaceuticals                                    | TRiM (GalNAc-siRNA conjugates)                                                                   | Dyslipidemia                                                    | Phase 1/2            | NCT03747224 |
| siRNA        | ARO-HSD                           | Arrowhead Pharmaceuticals                                    | (TRiM)-ligand conjugate                                                                          | Non-alcoholic steatohepatitis (NASH)                            | Phase 1/2            | NCT04202354 |
| siRNA        | Tivanisiran (SYL1001)             | Sylentis                                                     | Self-delivered (Hybridized single strand complementary RNA)                                      | Dry eye disease                                                 | Phase 3              | NCT03108664 |
| siRNA        | BMT101                            | Hugel                                                        | Self-delivered                                                                                   | Hypertrophic scar                                               | Phase 2              | NCT04012099 |
| siRNA        | Inclisiran                        | Novartis Pharmaceuticals                                     | GalNAc conjugate (Modified siRNA conjugated to triantennary N-acetylgalactosamine carbohydrates) | Homozygous familial hypercholesterolemia                        | Phase 3              | NCT03851705 |
| siRNA        | Lumasiran                         | Alnylam Pharmaceuticals                                      | GalNAc conjugate (ESC)                                                                           | Primary hyperoxaluria type 1                                    | Phase 3 (commercial) | NCT03681184 |
| siRNA        | DCR-PHXC                          | Dicerna Pharmaceuticals                                      | GalNAc conjugate (GalXC)                                                                         | Primary hyperoxaluria type 1 and 2                              | Phase 2              | NCT03847909 |
| siRNA        | Fitusiran                         | Genzyme (Sanofi) and Alnylam                                 | GalNAc conjugate (N-acetylgalactosamine conjugation)                                             | Hemophelia A, B; rare bleeding diseases                         | Phase 3              | NCT03417245 |
| siRNA        | Vutrisiran                        | Alnylam Pharmaceuticals                                      | GalNAc conjugate (ESC)                                                                           | Transthyretin amyloidosis (ATTR)                                | Phase 3              | NCT03759379 |
| siRNA        | Cemdisiran                        | Alnylam Pharmaceuticals                                      | GalNAc conjugate (N-acetylgalactosamine conjugation)                                             | IgA nephropathy (IgAN), Berger disease, Glomerulonephritis, IgA | Phase 2              | NCT03841448 |
| siRNA        | siG12D LODER                      | Silenseed Ltd.                                               | Polymer matrix (poly (lactic-co-glycolic) acid (PLGA))                                           | Locally advanced pancreatic cancer                              | Phase 2              | NCT01676259 |
| mRNA         | mRNA-1273                         | Moderna                                                      | Ionizable LNP (SM-102, PEG-2000-DMG, DSPC, cholesterol)                                          | SARS-COV-2                                                      | Phase 3              | NCT04405076 |
| mRNA         | mRNA-4157                         | Moderna                                                      | Ionizable LNP                                                                                    | Melanoma                                                        | Phase 2              | NCT03897881 |
| mRNA         | mRNA-1647                         | Moderna                                                      | Ionizable LNP                                                                                    | Cytomegalovirus                                                 | Phase 2              | NCT04232280 |
| mRNA         | mRNA-3704                         | Moderna                                                      | Ionizable LNP                                                                                    | Methylmalonic acidemia                                          | Phase 1/2            | NCT03810690 |
| mRNA         | mRNA 2416                         | Moderna                                                      | Ionizable LNP                                                                                    | Relapsed/refractory solid tumor malignancies, lymphoma          | Phase 1/2            | NCT03323398 |
| mRNA         | BI 1361849 (CV9202)               | CureVac, Boehringer Ingelheim, Ludwig Cancer Research        | Combination of modified mRNA and protamine complexed mRNA                                        | Metastatic non-small cell lung cancer                           | Phase1/2             | NCT03164772 |
| mRNA         | W\_pro1                           | BioNTech RNA Pharmaceuticals                                 | Lipoplex                                                                                         | Metastatic castration resistant prostate cancer                 | Phase1/2             | NCT04382898 |
| mRNA         | PF-07302048 (BNT162)              | Pfizer and BioNTech                                          | LNP (ALC-0315, ALC-0159, DSPC, and cholesterol)                                                  | SARS-CoV-2                                                      | Phase 2/3            | NCT04368728 |
| DNA          | AD26.COV2.S                       | Johnson & Johnson                                            | Adenovirus serotype 26 vector                                                                    | SARS-CoV-2                                                      | Phase 3              | NCT04614948 |
| DNA          | AZD1222(ChAdOx1 nCoV-19)          | AstraZeneca, Oxford University                               | Adenovirus vector                                                                                | SARS-CoV-2                                                      | Phase 3              | NCT04516746 |
| DNA          | Ad5-nCoV                          | CanSino Biologics                                            | Adenovirus type-5 vector                                                                         | SARS-CoV-2                                                      | Phase 3              | NCT04540419 |
